PSMA Theranostics: Current Status and Future Directions

Rahbar, Kambiz; Afshar Oromieh, Ali; Jadvar, Hossein; Ahmadzadehfar, Hojjat (2018). PSMA Theranostics: Current Status and Future Directions. Molecular imaging, 17, p. 1536012118776068. SAGE Publications 10.1177/1536012118776068

[img]
Preview
Text
1536012118776068.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (845kB) | Preview

Prostate-specific membrane antigen (PSMA) is a promising target for imaging diagnostics and targeted radionuclide therapy (theranostics) of prostate cancer and its metastases. There is increasing evidence of encouraging response rates and a low toxicity profile of radioligand therapy (RLT) of metastatic castration-resistant prostate cancer using 177Lu-labeled PSMA ligands. In this article, we review the current status of diagnostics and therapy using radiolabeled PSMA ligands. We also suggest protocols for patient selection criteria and conduct of PSMA-based RLT. Challenges and opportunities of PSMA theranostics are discussed.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine

UniBE Contributor:

Afshar Oromieh, Ali

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1536-0121

Publisher:

SAGE Publications

Language:

English

Submitter:

Sabine Lanz

Date Deposited:

01 Feb 2019 15:09

Last Modified:

29 Oct 2019 15:49

Publisher DOI:

10.1177/1536012118776068

PubMed ID:

29873291

BORIS DOI:

10.7892/boris.125616

URI:

https://boris.unibe.ch/id/eprint/125616

Actions (login required)

Edit item Edit item
Provide Feedback